SABR for limited metastatic cancer (ID-COMET trial)
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing clinical trials.
This study tests a precise radiation technique called SABR to treat cancer that has spread to a few spots. It aims to see if this approach can help control the cancer better than usual treatment, especially for lung, prostate, colorectal, or other solid tumors with limited spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old, or have a parent or guardian who can agree for you.
- You should be able to walk and care for yourself, or need only some help (ECOG score 3 or less).
- Your doctor expects you to live at least 6 months longer.
- You must have a cancer that has spread to no more than 10 spots (or fewer if you have certain types like lung, prostate, or colorectal).
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must agree to use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise, high-dose radiation treatment (SABR) for people whose cancer has spread to a few spots (up to 5) and is not growing in the brain or been previously treated with radiation in those same spots.
This feasibility study tests whether MRI-guided, highly focused radiation can be safely delivered to tumors in the abdomen or central lung. It may help patients with a small number of metastases by aiming treatment more precisely and gathering detailed outcomes for future care.
This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.
This trial compares a newer, more targeted type of radiation (hotspot SABR) with the standard SABR approach for people with early-stage non-small cell lung cancer. The goal is to see if the newer method works just as well or better while possibly reducing side effects.
This trial tests whether adding focused, high-dose radiation (SABR) to standard drug therapy can better control cancer that has spread to a few spots in the body. It is for people starting or resuming cancer medicines for newly found or growing metastases.
This trial looks at whether giving radiation treatment to tumors in people with a limited number of metastases can help control the cancer. It is for adults with certain cancer types that have spread to specific organs, and who can manage daily activities with little or no help.
Hear when a new Oligometastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.